Delving into the Latest Updates on TF 2-targeted cancer therapy(Immunomedics, Inc.) with Synapse

Overview

Basic Info

Drug Type

Radiolabeled antibody, Diagnostic radiopharmaceuticals, Bispecific antibody

Synonyms

Dual modality imaging, Ga68 Labeled TF-2

+ [1]

Target

CEACAM5 x Histamine succinyl glycine

Mechanism

CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), Histamine succinyl glycine inhibitors(Histamine succinyl glycine inhibitors), PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Breast CancerNon-Small Cell Lung CancerSmall Cell Lung Cancer+ [2]

Inactive Indication

Cutaneous Mastocytosis

Originator Organization

Immunomedics, Inc.

Active Organization

Immunomedics, Inc.IBC Pharmaceuticals, Inc.

Inactive Organization

Nantes University HospitalJADO Technologies GmbH

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Prospective Multicentric Optimization and Phase I/II Study of Pretargeted Radioimmunotherapy (PRAIT) Using Anti-CEA x Anti-HSG TF2 Bispecific Antibody (bsMAb) and 177Lu-IMP-288 Peptide in Patients With CEA-expressing Small Cell Lung Carcinoma (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

Lung cancer is currently the leading cause of cancer death in both men and women in Europe, with an estimated 250000 new cases diagnosed in 2005. The continued poor outcome of patients indicates that the current recommended regimens are falling short. In addition, many of the commonly used chemotherapy agents are associated with severe nonhematologic toxicities that are often cumulative and nonreversible and impair quality of life in this essentially palliative setting. Therefore, agents with novel mechanisms of action and superior safety profiles need to be investigated. More than 50% of lung cancer shows carcinoembryonic antigen (CEA) expression and anti-CEA radioimmunotherapy (RAIT) could be used. The investigators group showed that pretargeted RAIT (PRAIT) using bispecific antibody (bsMAb) can deliver a higher radiation dose to a tumor than a directly radiolabeled anti-CEA antibody, and shows improved anti-tumor efficacy. This clinical trial is designed to assess PRAIT using an entirely new recombinant anti-CEA bsMAb and a 177Lu-labeled peptide for the treatment of CEA-expressing small cell lung cancers (SCLC) or CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

Start Date01 Jun 2011

Sponsor / Collaborator-

100 Clinical Results associated with TF 2-targeted cancer therapy(Immunomedics, Inc.)

Login to view more data

100 Translational Medicine associated with TF 2-targeted cancer therapy(Immunomedics, Inc.)

Login to view more data

100 Patents (Medical) associated with TF 2-targeted cancer therapy(Immunomedics, Inc.)

Login to view more data

35

Literatures (Medical) associated with TF 2-targeted cancer therapy(Immunomedics, Inc.)

01 Jun 2024·Journal of Infection and Chemotherapy

Antiviral activity of theaflavins against Zika virus in vivo and in vitro

Letter

Author: Wang, Tiecheng ; Lv, Chaoxiang ; Luo, Rongbo ; Yue, Donghui ; Sima, Mingwei ; Deng, Xiuwen ; Guo, Jin ; Gao, Yuwei ; Qi, Jing

INTRODUCTIONThe prevalence and infection of the Zika virus (ZIKV) have recently posed a major threat to global public health security. However, there is currently a lack of specific vaccines and effective antiviral drugs for ZIKV infection.METHODSTheaflavins TF1 and TF2 were selected by evaluating the anti-Zika virus activity of four kinds of theaflavins in vitro. Subsequently, in vivo, we investigated the effects of TF1 and TF2 on weight, survival, tissue viral load, and cytokines in ZIKV-infected mice.RESULTSWe compared the anti-ZIKV activity of four theaflavins (TFs) in cells and found that TF1 and TF2b significantly inhibited the replication of ZIKV/Z16006 toxic strain in BHK and Vero cells by inhibiting the replication and release of ZIKV, while no similar effects were observed for TF2a and TF3. In vivo assay, we only found that TF2b improved the survival rate of infected mice. In tissues of ZIKV-infected mice, the viral load was higher in spleen and blood, followed by liver, epididymis, and testis, the lowest in muscle. Additionally, TF2b treatment significantly reduced the expression of cytokines (IL-6, IL-1β, TNF-α) and chemokines (CCL2, CCL5, CXCL10) induced by ZIKV infection.CONCLUSIONSThese findings suggest that TF2b has a potent antiviral effect and can be used as a potential candidate for the treatment of ZIKV infection.

01 Sep 2021·Journal of Nuclear MedicineQ1 · MEDICINE

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study

Q1 · MEDICINE

Article

Author: Carlier, Thomas ; Faivre-Chauvet, Alain ; Toulgoat, Frederique ; Kraeber-Bodere, Francoise ; Goldenberg, David M ; Drui, Delphine ; Barbet, Jacques ; Bodet-Milin, Caroline ; Rauscher, Aurore ; Ansquer, Catherine ; Frampas, Eric ; Couturier, Olivier ; Cerato, Evelyne ; Masson, Damien ; Sharkey, Robert M ; Bourgeois, Mickael ; Rohmer, Vincent

Pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the ⁶⁸Ga-labeled IMP288 peptide for immuno-PET have been optimized in a first-in-humans study performed on medullary thyroid carcinoma (MTC) patients (the iPET-MTC study). The aim of this post hoc analysis was to determine the sensitivity of immuno-PET in relapsing MTC patients, in comparison with conventional imaging and ¹⁸F-l-dihydroxyphenylalanine (¹⁸F-DOPA) PET/CT. Methods: Twenty-five studies were analyzed in 22 patients. All patients underwent immuno-PET 1 and 2 h after ⁶⁸Ga-IMP288 injection pretargeted by TF2, in addition to neck, thoracic, abdominal, and pelvic CT; bone and liver MRI; and ¹⁸F-DOPA PET/CT. The gold standard was histology or confirmation by one other imaging method or by imaging follow-up. Results: In total, 190 lesions were confirmed by the gold standard: 89 in lymph nodes, 14 in lungs, 46 in liver, 37 in bone, and 4 in other sites (subcutaneous tissue, heart, brain, and pancreas). The number of abnormal foci detected by immuno-PET was 210. Among these, 174 (83%) were confirmed as true-positive by the gold standard. Immuno-PET showed a higher overall sensitivity (92%) than ¹⁸F-DOPA PET/CT (65%). Regarding metastatic sites, immuno-PET had a higher sensitivity than CT, ¹⁸F-DOPA PET/CT, or MRI for lymph nodes (98% vs. 83% for CT and 70% for ¹⁸F-DOPA PET/CT), liver (98% vs. 87% for CT, 65% for ¹⁸F-DOPA PET/CT, and 89% for MRI), and bone (92% vs. 64% for ¹⁸F-DOPA PET/CT and 86% for MRI), whereas sensitivity was lower for lung metastases (29% vs. 100% for CT and 14% for ¹⁸F-DOPA PET/CT). Tumor SUV_max at 60 min ranged from 1.2 to 59.0, with intra- and interpatient variability. Conclusion: This post hoc study demonstrates that anti-carcinoembryonic antigen immuno-PET is an effective procedure for detecting metastatic MTC lesions. Immuno-PET showed a higher overall sensitivity than ¹⁸F-DOPA PET/CT for disclosing metastases, except for the lung, where CT remains the most effective examination.

01 Mar 2021·European Journal of Nuclear Medicine and Molecular ImagingQ1 · MEDICINE

Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study

Q1 · MEDICINE

Article

Author: Cerato, E ; Barbet, J ; David, A ; Rousseau, C ; Kraeber-Bodere, F ; Rauscher, A ; Masson, D ; Touchefeu, Y ; Bodet-Milin, C ; Bossard, C ; Bourgeois, M ; Faivre-Chauvet, A ; Eugène, T ; Bailly, C ; Frampas, E ; Sharkey, R M ; Carlier, T ; Goldenberg, D M

INTRODUCTIONThis pilot study evaluated the imaging performance of pretargeted immunological positron emission tomography (immuno-PET) using an anti-carcinoembryonic antigen (CEA) recombinant bispecific monoclonal antibody (BsMAb), TF2 and the [⁶⁸Ga]Ga-labelled HSG peptide, IMP288, in patients with metastatic colorectal carcinoma (CRC).PATIENTS AND METHODSPatients requiring diagnostic workup of CRC metastases or in case of elevated CEA for surveillance were prospectively studied. They had to present with elevated CEA serum titre or positive CEA tumour staining by immunohistochemistry of a previous biopsy or surgical specimen. All patients underwent endoscopic ultrasound (EUS), chest-abdominal-pelvic computed tomography (CT), abdominal magnetic resonance imaging (MRI) and positron emission tomography using [¹⁸F]fluorodeoxyglucose (FDG-PET). For immuno-PET, patients received intravenously 120 nmol of TF2 followed 30 h later by 150 MBq of [⁶⁸Ga]Ga-labelled IMP288, both I.V. The gold standard was histology and imaging after 6-month follow-up.RESULTSEleven patients were included. No adverse effects were reported after BsMAb and peptide injections. In a per-patient analysis, immuno-PET was positive in 9/11 patients. On a per-lesion analysis, 12 of 14 lesions were positive with immuno-PET. Median SUV_max, MTV and TLG were 7.65 [3.98-13.94, SD 3.37], 8.63 cm³ [1.98-46.64; SD 14.83] and 37.90 cm³ [8.07-127.5; SD 43.47] respectively for immuno-PET lesions. Based on a per-lesion analysis, the sensitivity, specificity, positive-predictive value and negative-predictive value were, respectively, 82%, 25%, 82% and 25% for the combination of EUS/CT/MRI; 76%, 67%, 87% and 33% for FDG-PET; and 88%, 100%, 100% and 67% for immuno-PET. Immuno-PET had an impact on management in 2 patients.CONCLUSIONThis pilot study showed that pretargeted immuno-PET using anti-CEA/anti-IMP288 BsMAb and a [⁶⁸Ga]Ga-labelled hapten was safe and feasible, with promising diagnostic performance.TRIAL REGISTRATIONClinicalTrials.gov NCT02587247 Registered 27 October 2015.

100 Deals associated with TF 2-targeted cancer therapy(Immunomedics, Inc.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colorectal Cancer	Phase 3	FR	Nantes University Hospital	-
Breast Cancer	Phase 2	-	Immunomedics, Inc.	-
Non-Small Cell Lung Cancer	Phase 2	-	Immunomedics, Inc.	-
Small Cell Lung Cancer	Phase 2	-	Immunomedics, Inc.	-
Thyroid Cancer	Phase 2	-	Immunomedics, Inc.	-
Cutaneous Mastocytosis	Phase 1	DE	JADO Technologies GmbH	01 Apr 2007
Colorectal Cancer	Phase 1	FR	Nantes University Hospital	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IAS2001	Not Applicable	-	1,309	Nelfinavir	oxcaymcuky(srszvkydxr) = zeffuqqbeu ngzdfgcjqn (fmuhauxksa ) View more	-	01 Jan 2001
				Dual NRTIs	oxcaymcuky(srszvkydxr) = avaqlplekc ngzdfgcjqn (fmuhauxksa ) View more